The six month observational study of 91 adults with moderate joint overall health challenges, carried out by scientists at the iminosugar analysis firm PhytoQuest Restricted, concludes that just 20 mgs everyday of the supplement substantially enhanced a variety of joint overall health scores.
The analysis, published in Present Rheumatology Testimonials, also states that the benefits have been dose dependent, so a greater Q-Actin concentration of one hundred mg decreased the OA-associated parameters by a higher extent.
The authors hence suggests there could be a personalised supplementation strategy needed with a certain dosage for an optimum activity for a offered age.
Discussing the mechanism of action, the authors hypothesise it is due to the anti-inflammatory activity of idoBR1 – the iminosugar amino acid isolated from cucumber.
Q-actin and iminosugars
Q-actin, marketed by the iminosugars developer IminoTech Inc, is a cucumber (Cucumis sativus L.) extract containing the iminosugar ido-BR1 standardized to > 1%.
Iminosugars are analogues of sugars in which the oxygen is replaced by a nitrogen atom. This substitution prevents typical metabolism resulting in inhibition of glycosidases and glycosyltransferases.
These compounds are attracting interest as therapeutic agents due to their capacity to interact with human glycosidases, other proteins, and sugar receptors.
InimoTech says Q-actin operates by inhibiting Tumor Necrosis Aspect alpha (TNF-α), a chemical messenger immune cells release to support orchestrate immune program responses to prospective threats or broken tissues.
A previously published randomised, double-blinded clinical study involving 122 adults reported that 20 mgs of Q-actin everyday substantially enhanced joint overall health in comparison with two,700 mgs of glucosamine-chondroitin more than a six-month period. Subjects have been evaluated at 30-day intervals applying WOMAC, VAS and LFI. Q-actin decreased WOMAC scores by 70% more than six months.
Earlier studies showed Q-actin/ido-BR1 decreased LPS-induced pro-inflammatory cytokine tumour necrosis element alpha (TNFα) in both ex vivo human serum and THP-1 cells. TNFα can drive degenerative adjustments such as in joints when chronically elevated. Analysis shows that idoBR1 operates in a dose-dependent manner to cut down inflammatory markers, including LPS-induced production of TNFα, IL-six, nitric oxide and the transcription element NF-κB.
Study Style and Benefits
The current study enrolled 101 subjects with moderate osteoarthritis, 91 of which have been evaluable. Subjects have been divided into 3 groups taking a placebo or 20 mgs or one hundred mgs of Q-actin everyday for six months. Following a baseline evaluation, subjects have been evaluated at 30-day intervals applying the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Visual Analogue Scale (VAS) and Lequesne’s Functional Index (LFI).
Each Q-actin groups seasoned important reductions in discomfort and improvements in other joint function parameters at every single point of the study by every single evaluation strategy. For instance, subjects taking 20 mgs everyday of Q-actin seasoned a 32% improvement in WOMAC scores more than six months, compared with a five% improvement for the placebo group. The Q-actin overall health rewards have been dose dependent. The WOMAC score of the one hundred milligram-group elevated 39% more than the duration of the study.
Shil Kothari, IminoTech Chief Executive Officer states: “It is outstanding that a everyday serving of only 20 mgs of Q-actin developed important improvements in joint function, like the capacity to total everyday activities such as applying stairs, purchasing and operating at dwelling.
“Q-actin’s everyday serving size is a modest fraction of major joint overall health dietary supplement components. It opens the door to numerous new joint overall health item formats and applications.”
Supply: Present Rheumatology Testimonials
Standardised ido-BR1 Cucumber Extract Enhanced Parameters Linked to Moderate Osteoarthritis in a Placebo-controlled Study.
Nash. R. J., et al
One thought on “Market study finds joint overall health rewards of cucumber extract containing iminosugar”